Form D · Biotechnology

DOSE Therapeutics, Inc.

Dallas, TX · CIK 0001927425

Offering snapshot reported May 13, 2022 · SEC filing

Reported sold
$10M
Offering amount: $10M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 30, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$5M$10MMay 12, 2022: $10,000,000.00May 12, 2022May 13, 2022: $10,000,000.00May 13, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 13, 2022Amendment$10,000,000$0vs May 12, 202220SEC filing
May 12, 2022Initial$10,000,000No comparison20SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-445465

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANone

Source: Form D, filed May 13, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Bakes Executive
Blair Lapointe Director
Steven L. Mcknight Director
John Fulton Murray Director, Executive
Deepak Nijhawan Director
Mc Henry T. Tichenor Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3060 Pegasus Park Building 6
Dallas, TX, 75247